Floatz logo

Boditrectinib

Phase 1

Handok Inc.Small moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the Phase 1 cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
M.D. Anderson Cancer Center
Phase 1CC
Irinotecan
M.D. Anderson Cancer Center
Phase 1CC
Fludarabine
M.D. Anderson Cancer Center
Phase 1CC
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines.
M.D. Anderson Cancer Center
Phase 1CC
sar445877
M.D. Anderson Cancer Center
Phase 1CC

View all 11 →

Same molecule, other indications

Boditrectinib is also rated in:

Solid Tumor, AdultDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →